In the phase 3 DESTINY-Lung04 trial, patients with HER2-mutant advanced non-small cell lung cancer treated with Enhertu went ...

A reflection on shame, vulnerability and transformation, and how driftwood, the ocean and presence helped reshape one man's ...

Patients with early-stage EGFR-mutated non-small cell lung cancer (NSCLC) who took Tagrisso (osimertinib) for three years ...

In this installment of Clinical Trial Corner, Dr. Dina Khalaf, a clinical associate professor in the University of Florida ...

WCLC 2026 brought new lung cancer data on HER2-mutant, PD-L1-positive and EGFR exon 20 insertion-positive non-small cell lung ...

A dedicated movement space can serve as a survivorship anchor, reinforcing identity, agency, and continuity through training ...

A peritoneal mesothelioma diagnosis at 21, five months postpartum, underscores the psychosocial burden of rare malignancy in ...

Now, survivorship means that I have been through an experience that has forever shaped who I am, how I respond and what I ...

Biomarker-matched agents increasingly supplant empiric chemo, with approvals typically starting in refractory metastatic ...

The FDA granted final approval to OMCAZIO, a new cabozantinib capsule formulation for certain patients with kidney, liver and ...

Patients should never view the first denial as the final answer. Whether it's Medicare, Medicaid, an employer-sponsored plan ...

The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Hyrnuo (sevabertinib) for adults with locally ...